Sun Life to proactively offer second opinions on cancer diagnoses when members file a cancer-related claim

Sun Life (NYSE:SLF) will proactively offer its Expert Cancer Review (ECR) second-opinion service to members who file a cancer-related disability or supplemental health claim, with outreach occurring closer to diagnosis.

Rhea-AI Summary

Sun Life (NYSE:SLF) will proactively offer its Expert Cancer Review (ECR) second-opinion service to members who file a cancer-related disability or supplemental health claim, with outreach occurring closer to diagnosis. From 2024–2025, 41% of second opinions led to a change in diagnosis, diagnostic strategy, or treatment.

Sun Life links ECR through employer stop-loss policies, integrates ECR with Health Navigator personal advisors, and automatically screens stop-loss cancer claimants for critical illness/cancer benefits to streamline payments.

Positive

• Proactive outreach to members at time of cancer claim filing
• 41% of second opinions changed diagnosis, strategy, or treatment (2024–2025)
• Integrated services via Health Navigator and stop-loss policies
• Automatic critical illness screening and direct payment when eligible

Negative

• High cancer claim costs: ~$235,000–$300,000 average annual claim (2025 report)
• Rising workforce exposure: solid cancers >40% of stop-loss spend for ages 40–59

Argus Feb 23 session

-2.67% close to close Open Argus

Details

News Market Reaction – SLF

In the Feb 23 session, SLF declined 2.67%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights Sun Life U.S. expanding Expert Cancer Review outreach so members filing...

Analysis

This announcement highlights Sun Life U.S. expanding Expert Cancer Review outreach so members filing cancer-related disability or supplemental health claims receive proactive second opinions. Historical data show 41% of such reviews led to changes in diagnosis or treatment strategy, against average cancer claim costs of about $235,000 to over $300,000. Combined with prior earnings strength and benefits integration efforts, investors may watch how these services support stop-loss performance and employer adoption over time.

Key Figures

Changed diagnosis/treatment: 41% Average cancer claim cost: $235,000 Average blood cancer cost: Over $300,000 +3 more

Changed diagnosis/treatment

41%

Second opinions facilitated by Sun Life from 2024–2025

Average cancer claim cost

$235,000

Annual cost for malignant neoplasm (solid cancers) in 2025 report

Average blood cancer cost

Over $300,000

Annual cost for leukemia, lymphoma, multiple myeloma in 2025 report

Solid cancer spend share

More than 40%

Share of total medical spend in 2024 Sun Life stop-loss claims

High-risk age band

Ages 40–59

Adults where solid cancers made up more than 40% of spend

Younger diagnosis trend

Under age 50

NIH cited increase in cancer prevalence among people under 50

Historical Context

5 past events · Latest: Feb 19

5 events

1. Feb 19

   Management/board role

   24h Move

   -1.8%

   Chief dental officer joined TeamSmile board, reinforcing focus on dental access.

2. Feb 11

   Dividend declaration

   24h Move

   -0.9%

   Declared Q1 2026 dividends, including $0.92 per common share, matching prior quarter.

3. Feb 11

   Earnings results

   24h Move

   -0.9%

   Reported strong Q4 and 2025 with higher underlying net income, EPS, and AUM.

4. Feb 11

   Workplace awards

   24h Move

   -0.9%

   Sun Life U.S. received multiple Top Place to Work awards in Kansas City.

5. Feb 05

   Community program

   24h Move

   -0.7%

   Opened applications for 2026 Health Access Hero Awards with grant funding.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

stop-loss policy, critical illness, supplemental health, oncology specialist, +2 more

6 terms

stop-loss policy financial

"ECR services available through their employers' Sun Life stop-loss policy."

A stop-loss policy is a preset rule to automatically sell a stock when its price falls to a specified level, designed to limit how much an investor can lose on a position. Think of it like a safety valve on a machine: it closes off further damage without requiring constant attention, helping investors control risk and protect capital, though it can also trigger sales during short-term market swings.

critical illness financial

"a cancer-related claim for disability or critical illness/cancer benefits"

A critical illness is a severe medical condition—such as heart attack, stroke, or advanced cancer—that poses a high risk of death or long-term disability and typically requires intensive, costly treatment. For investors, the label matters because it shapes healthcare spending, insurance payouts, and business continuity: think of it as a sudden, serious road crash for a person’s health that can trigger large medical bills, insurance claims, drug and device demand, and shifts in company costs and value.

supplemental health financial

"critical illness/cancer (supplemental health) insurance, Sun Life will reach out"

Supplemental health is additional insurance or benefit coverage that fills gaps left by a person’s main health plan, such as paying for dental, vision, hospital stays, critical illness, or out-of-pocket costs. Think of it like a spare tire or phone case: it doesn’t replace the main protection but reduces the financial shock from specific events. For investors, demand, pricing and regulatory rules for these add-ons affect insurers’ revenue mix, profit stability and claim risk.

oncology specialist medical

"second opinion from an independent oncology specialist, helping to ensure"

An oncology specialist is a doctor who diagnoses and treats cancer, from choosing therapies to managing side effects and monitoring patient progress. For investors, their role matters because these specialists influence whether new cancer drugs are adopted, how clinical trial results are interpreted, and how quickly treatments reach patients—similar to how a trusted mechanic’s endorsement affects whether a new car part catches on. Their opinions and prescribing patterns can materially affect a company’s sales and regulatory success.

malignant neoplasm medical

"average annual cost of a cancer claim ranged from about $235,000 for malignant neoplasm"

A malignant neoplasm is a medical term for a cancerous growth of cells that can invade nearby tissue and spread to other parts of the body. For investors, it matters because diagnoses, drug trial results, approvals, or liabilities tied to such cancers can materially affect healthcare costs, drug and device company revenues, and regulatory outcomes—think of it like a fault in a product line that can both damage performance and trigger costly fixes.

multiple myeloma medical

"over $300,000 for leukemia, lymphoma, and multiple myeloma (blood cancers)."

A cancer of the blood that starts in plasma cells, the immune system’s antibody-producing cells in bone marrow. It behaves like a factory where the workers go rogue, crowding out healthy cells and causing bone damage, anemia and infections; treatments and trial results can sharply affect drug sales, regulatory approvals and company valuations, so progress or setbacks are closely watched by investors.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Expert Cancer Review services help boost members' confidence in their cancer treatment plan

WELLESLEY, Mass., Feb. 23, 2026 /PRNewswire/ -- Sun Life U.S. is expanding access to its Expert Cancer Review (ECR) service by proactively engaging members closer to the time of diagnosis. When a member files a cancer-related claim for disability or critical illness/cancer (supplemental health) insurance, Sun Life will reach out to connect them to ECR services available through their employers' Sun Life stop-loss policy. Members must also be enrolled in Sun Life disability or supplemental benefits.

ECR provides members diagnosed with cancer an objective, documented second opinion from an independent oncology specialist, helping to ensure they get the right care and feel confident in their chosen treatment plan. From 2024 – 2025, 41% of the second opinions facilitated by Sun Life resulted in a change in diagnosis or shift in diagnostic strategy or treatment.

"Offering a second opinion when our members file a cancer-related claim for disability or critical illness/cancer benefits enables us to support them closer to the time of their diagnosis," said Joi Tillman, president, Group Benefits, Sun Life U.S. "Expert Cancer Review will help members feel more confident in their treatment while their Sun Life disability and supplemental health plans replace their income and pay cash benefits to help them cover out-of-pocket costs. This is a great next step in integrating our Health and Risk Solutions services with our Group Benefits member experience, following the initial expansion of our Health Navigator personal care advisor services last year."

Cancer continues to be one of the most frequently diagnosed and costliest diseases to treat in the U.S. According to Sun Life's 2025 High Cost Claims Report, the average annual cost of a cancer claim ranged from about $235,000 for malignant neoplasm ("solid" cancers) to over $300,000 for leukemia, lymphoma, and multiple myeloma (blood cancers). While ECR is already available through an employer's Sun Life medical stop-loss policy, members can now receive proactive outreach when filing a cancer-related disability or supplemental health claim with Sun Life – engaging them earlier in the process, when the expert second opinion can be more valuable to the member.

According to the National Institute of Health, cancer diagnoses have become more prevalent in those under age 50 – people still in the workforce. Sun Life's High Cost Claims Report showed that solid cancers, particularly in adults ages 40-59, made up more than 40% of the total medical spend across Sun Life's stop-loss claims for 2024. As more people in the workforce encounter cancer diagnoses, employee benefits can play a pivotal role in increasing access to care and support.

"Expert second opinions on cancer can avoid misdiagnoses and spare people unnecessary treatments, as well as lead to better, more tailored therapies," said Jen Collier, president, Health and Risk Solutions, Sun Life U.S. "More efficient and effective care also drives down costs, which benefits both the member and their employer. Proactively connecting eligible members to ECR will support our employer clients as they help their employees stay at or return to work, and drive better health outcomes overall."

Sun Life has continuously evolved its approach to benefits integration to better support those with cancer. In addition to offering healthcare navigation and ECR, Sun Life automatically screens a member for critical illness/cancer benefits when there is a stop-loss (high-dollar) claim filed for cancer. If they are covered, the member receives their benefit payment without needing to file a separate claim.

ECR is facilitated by Sun Life Health Navigator, a service that provides personal health advisors who help people get the right care, doctors and treatment to support them through their medical journey. Second opinions are an integral part of Health Navigator services, whether for cancer or other diagnoses.

To learn more about impacts of cancer in the workforce and the support of Sun Life benefits, visit www.sunlife.com/cancer.

About Sun Life
Sun Life is a leading international financial services organization providing asset management, wealth, insurance and health solutions to individual and institutional Clients. Sun Life has operations in a number of markets worldwide, including Canada, the U.S., the United Kingdom, Ireland, Hong Kong, the Philippines, Japan, Indonesia, India, China, Australia, Singapore, Vietnam, Malaysia and Bermuda. As of December 31, 2025, Sun Life had total assets under management of C$1.6 trillion. For more information, please visit www.sunlife.com.

Sun Life Financial Inc. trades on the Toronto (TSX), New York (NYSE) and Philippine (PSE) stock exchanges under the ticker symbol SLF.

Sun Life U.S. is one of the largest providers of employee and government benefits, helping approximately 50 million Americans access the care and coverage they need. Through employers, industry partners and government programs, Sun Life U.S. offers a portfolio of benefits and services, including dental, vision, disability, absence management, life, supplemental health, medical stop-loss insurance, and healthcare navigation. Sun Life employs more than 8,300 people in the U.S., including associates in our partner dental practices and affiliated companies in asset management. Group insurance policies are issued by Sun Life Assurance Company of Canada (Wellesley Hills, Mass.), except in New York, where policies are issued by Sun Life and Health Insurance Company (U.S.) (Lansing, Mich.). For more information visit our website and newsroom.

Media contacts

Devon Fernald
Sun Life U.S.
Devon.Portney.Fernald@sunlife.com
781-800-3609

Connect with Sun Life U.S.

Facebook  LinkedIn

View original content to download multimedia:https://www.prnewswire.com/news-releases/sun-life-to-proactively-offer-second-opinions-on-cancer-diagnoses-when-members-file-a-cancer-related-claim-302694910.html

SOURCE Sun Life U.S.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What change did Sun Life (SLF) make to Expert Cancer Review on Feb 23, 2026?

Sun Life will proactively connect eligible members to ECR when they file a cancer-related claim, earlier in care decision-making. According to Sun Life, outreach occurs for members with disability or supplemental health claims tied to an employer stop-loss policy.

How often did Sun Life second opinions change care between 2024 and 2025 for SLF members?

Second opinions led to a change in diagnosis or care in 41% of cases between 2024–2025. According to Sun Life, that rate reflects facilitated expert reviews across their stop-loss and benefits programs.

What financial impact do cancer claims show in Sun Life's 2025 report for SLF investors?

Sun Life's 2025 report cites average annual cancer claim costs of about $235,000 to over $300,000. According to Sun Life, leukemia, lymphoma and multiple myeloma averaged over $300,000, stressing employer plan costs and benefits funding.

Who is eligible for the proactive Expert Cancer Review outreach at Sun Life (SLF)?

Members enrolled in Sun Life disability or supplemental health who file a cancer-related claim are eligible for proactive ECR outreach. According to Sun Life, employers must have a Sun Life stop-loss policy for ECR facilitation.

How does Sun Life's ECR link with Health Navigator for SLF members?

ECR is delivered through Sun Life Health Navigator personal advisors as part of integrated member support. According to Sun Life, advisors help arrange independent oncology second opinions and guide care navigation for diagnosed members.